How do you approach delivering ISRT to nodular lymphocyte predominant Hodgkin Lymphoma that has responded on FDG-PET/CT after chemotherapy?   

Does the stage at diagnosis affect your decision?



Answer from: Radiation Oncologist at Community Practice